This excerpt taken from the BMY DEF 14A filed Mar 23, 2009.
Overall company exceeded its 2008 financial targets as set forth on pages 20-21.
Delivered strong year-on-year worldwide sales growth on several products, including: Baraclude® 190%, Orencia® 189%, Abilify® 128%, Sustiva® 119% and Plavix® 117%.
Executed the successful sale of ConvaTec for $4.1 billion and the successful partial IPO of Mead Johnson Nutrition Company.
Made significant progress in reducing our geographic footprint, shrinking our mature brands portfolio and consolidating our manufacturing operations. These initiatives have
produced significant cost savings for the company.
Launched a new commercial model aimed at driving the companys next-generation biopharmaceutical strategy. Demonstrated strong leadership in unifying and mobilizing a
diverse global workforce to achieve sustainable competitive growth.
This excerpt taken from the BMY DEF 14A filed Mar 24, 2008.
Worldwide Pharmaceuticals achieved pretax earnings that were 110% of target.
Delivered strong sales growth versus 2006 on several products of strategic importance: Abilify® +27%, Sustiva® +17%, Reyataz® +17%, and Plavix® +10% (excluding
the effect of generic competition in 2006). Generated outstanding growth on new products: Baraclude® +221% and Sprycel® +488% (although Sprycel® fell slightly short of target).
Primary contributor in absolute dollar savings to the companys Productivity Transformation Initiative through the restructuring of Pharmaceutical Technical Operations.
Strongest performer among senior executives of promoting from within (71% of new executive positions filled internally) and holding executive voluntary turnover to a low
Effectively energized his organization and aligned diverse global markets around unifying goals despite the challenges that came with introducing broad scale transformational